News Out !!!!!25 Jul 2024 07:13
But not the one we are waiting for 😊
Oxford, UK - 25 July 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on the EpiSwitch® 3D genomics platform [1], announces its key-note presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, taking place on 3-6 September 2024 in Boston, MA, USA.
but some very interesting update on the US Cirt Obs study
Today, EpiSwitch® CiRT is the focus of an observational registry study in US: PROWES is a national IRB-approved study of the concordance of CiRT response prediction to the clinically observed response rate. It will further document the clinical application and utility of the assay for the treatment of multiple oncological indications. PROWES is projected to onboard up to dozen oncology institutions and enroll up to 2,500 patients. The study is being run under commercial terms through the CLIA labs in the US.